TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
BIO-TECHNE Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 24, 2026
$72.49−0.08 (-0.11%)
Close on Oct 19, 2026
- Market cap
- $11.40B
- P/E (TTM)
- 62.5
- Dividend yield
- 0.44%
Share price
+$10.63 (+17.18%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
BIO-TECHNE Corp saw revenue fall 0.4% to $1.22B over the twelve months to Jun 30, 2026. Operating income rose 146.3% to $251.89M, moving the operating margin from 8.4% to 20.7%. Free cash flow was $263.22M, up 2.6% from a year earlier.
Revenue
$1.22B
-0.4% vs. a year earlier
Operating income
$251.89M
+146.3% vs. a year earlier
Free cash flow
$263.22M
+2.6% vs. a year earlier
EPS, diluted
$1.16
+152.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $11.40B
- P/E ratio
- 62.5
- Price to sales
- 9.38
- Price to book
- 5.41
- Dividend yield
- 0.44%
- Free cash flow yield
- 2.31%
Fundamentals
- Revenue
- $1.22B
- EPS, diluted
- $1.16
- Free cash flow
- $263.22M
- Book value per share
- $13.41
- Diluted shares
- 157M
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
$1.22B-0.4% YoY
Gross profit
$799.07M+1.1% YoY
Operating income
$251.89M+146.3% YoY
Net income
–
EPS, diluted
$1.16+152.2% YoY
Free cash flow
$263.22M+2.6% YoY
Reported period